technica.bio / Longevity Pipeline
The longevity field, de-jargoned and de-hyped.
Longevity Pipeline
Companies engineering the biology of aging itself
From senolytics to partial epigenetic reprogramming — every serious shot at intervening on the aging process, mapped from mechanism to money. Most of it is still preclinical; the few human-stage assets are where the next decade gets decided.
Open the interactive Longevity Pipeline →19 companies tracked
| Company | Mechanism | Class | Stage | Evidence |
|---|---|---|---|---|
| Altos Labs | Partial epigenetic reprogramming | Cell / epigenetic | Preclinical | animal |
| Calico | Multiple (cellular senescence, neurodeg.) | Small molecule / biologic | Phase 1 | human |
| Retro Biosciences | Reprogramming, autophagy, plasma factors | Cell / small molecule | Preclinical | animal |
| Unity Biotechnology | Bcl-xL inhibition (senolytic) | Small molecule senolytic | Phase 2 | human |
| BioAge Labs | Apelin/APJ agonism; NLRP3 | Small molecule | Phase 2 | human |
| Loyal | Metabolic / IGF-1 reduction | Small molecule | Phase 3 | animal |
| Life Biosciences | Partial reprogramming (OSK via AAV) | Gene therapy | IND-enabling | animal |
| NewLimit | Epigenetic reprogramming (factor discovery) | Cell / epigenetic | Discovery | invitro |
| Rejuvenate Bio | Gene therapy (FGF21, sTGFβR2, klotho); reprogramming | AAV gene therapy | IND-enabling | animal |
| Turn Biotechnologies | mRNA epigenetic reprogramming | mRNA | Preclinical | animal |
| Gordian Biotechnology | In vivo pooled gene therapy screening | Platform / gene therapy | Preclinical | animal |
| Shift Bioscience | Reprogramming w/o dedifferentiation | Discovery / epigenetic | Preclinical | invitro |
| Insilico Medicine | TNIK inhibition (anti-fibrotic / senescence) | Small molecule (AI-discovered) | Phase 2 | human |
| Dorian Therapeutics | USP7 inhibition (senolytic) | Small molecule senolytic | IND-enabling | animal |
| Genflow Biosciences | SIRT6 (centenarian variant) gene therapy | AAV gene therapy | IND-enabling | animal |
| Elevian | GDF11 supplementation | Recombinant protein | Phase 1 | animal |
| Cambrian BioPharma | Multiple (mitophagy, senescence, mTOR) | Holding co / multi-asset | Phase 1 | human |
| Juvenescence | Multiple aging-focused assets | Holding co / multi-asset | Phase 1 | human |
| Fauna Bio | Comparative genomics (hibernators) | Small molecule | Preclinical | animal |
◢ Boom-cycle briefing
Get ahead of the next biotech boom.
New companies, stage changes, deal alerts and fresh tech briefs — one sharp email when the map moves.
Curated biotech intelligence, compiled for orientation — not investment advice. Company stages, deals and figures move fast; verify against ClinicalTrials.gov, company filings and primary sources before acting.